This is a preview of subscription content, log in via an institution to check access.
Notes
The PLATO trial was funded by AstraZeneca R&D, and the cost-effectiveness analysis was financially supported by AstraZeneca, Vietnam.
Reference
Nguyen TTT, et al. Cost-Effectiveness of Ticagrelor Compared with Clopidogrel in Patients with Acute Coronary Syndrome from Vietnamese Healthcare Payers' Perspective. Advances in Therapy : 11 Jun 2021. Available from: URL: https://doi.org/10.1007/s12325-021-01743-5
Rights and permissions
About this article
Cite this article
Ticagrelor cost effective in acute coronary syndrome in Vietnam. PharmacoEcon Outcomes News 881, 31 (2021). https://doi.org/10.1007/s40274-021-7827-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-7827-4